Daten aus dem Cache geladen. Pregabalin for neuropathic pain in adults | Webyourself Social...

Pregabalin for neuropathic pain in adults

0
3K

Pregabalin for neuropathic pain in adults

We included 45 studies lasting 2 to 16 weeks, with 11,906 participants ‐ 68% from 31 new studies. Oral Pregabalin doses of 150 mg, 300 mg, and 600 mg daily were compared with placebo. Postherpetic neuralgia, painful diabetic neuropathy, and mixed neuropathic pain predominated (85% of participants). High risk of bias was due mainly to small study size (nine studies), but many studies had unclear risk of bias, mainly due to incomplete outcome data, size, and allocation concealment.

Postherpetic neuralgia: More participants had at least 30% pain intensity reduction with pregabalin 300 mg than with placebo (50% vs 25%; RR 2.1 (95% confidence interval (CI) 1.6 to 2.6); NNTB 3.9 (3.0 to 5.6); 3 studies, 589 participants, moderate‐quality evidence), and more had at least 50% pain intensity reduction (32% vs 13%; RR 2.5 (95% CI 1.9 to 3.4); NNTB 5.3 (3.9 to 8.1); 4 studies, 713 participants, moderate‐quality evidence). More participants had at least 30% pain intensity reduction with pregabalin 600 mg than with placebo (62% vs 24%; RR 2.5 (95% CI 2.0 to 3.2); NNTB 2.7 (2.2 to 3.7); 3 studies, 537 participants, moderate‐quality evidence), and more had at least 50% pain intensity reduction (41% vs 15%; RR 2.7 (95% CI 2.0 to 3.5); NNTB 3.9 (3.1 to 5.5); 4 studies, 732 participants, moderate‐quality evidence). Somnolence and dizziness were more common with pregabalin than with placebo (moderate‐quality evidence): somnolence 300 mg 16% versus 5.5%, 600 mg 25% versus 5.8%; dizziness 300 mg 29% versus 8.1%, 600 mg 35% versus 8.8%.

Painful diabetic neuropathy: More participants had at least 30% pain intensity reduction with pregabalin 300 mg than with placebo (47% vs 42%; RR 1.1 (95% CI 1.01 to 1.2); NNTB 22 (12 to 200); 8 studies, 2320 participants, moderate‐quality evidence), more had at least 50% pain intensity reduction (31% vs 24%; RR 1.3 (95% CI 1.2 to 1.5); NNTB 22 (12 to 200); 11 studies, 2931 participants, moderate‐quality evidence), and more had PGIC much or very much improved (51% vs 30%; RR 1.8 (95% CI 1.5 to 2.0); NNTB 4.9 (3.8 to 6.9); 5 studies, 1050 participants, moderate‐quality evidence). More participants had at least 30% pain intensity reduction with pregabalin 600 mg than with placebo (63% vs 52%; RR 1.2 (95% CI 1.04 to 1.4); NNTB 9.6 (5.5 to 41); 2 studies, 611 participants, low‐quality evidence), and more had at least 50% pain intensity reduction (41% vs 28%; RR 1.4 (95% CI 1.2 to 1.7); NNTB 7.8 (5.4 to 14); 5 studies, 1015 participants, low‐quality evidence). Somnolence and dizziness were more common with pregabalin than with placebo (moderate‐quality evidence): somnolence 300 mg 11% versus 3.1%, 600 mg 15% versus 4.5%; dizziness 300 mg 13% versus 3.8%, 600 mg 22% versus 4.4%.

Pesquisar
Categorias
Leia Mais
Sports
Menggali Keunikan dan Keunggulan Game Slot25 Terbaru
    Dalam era digital yang serba cepat, Slot25 telah menjadi salah satu game slot...
Por Jak Islam 2024-04-27 12:49:53 0 875
Outro
The actual Energy associated with PBN Links : Exactly what They Are usually and also Precisely how They Effect SEO
  Since the world of SEO (Search Motor Optimization) is constantly progress, systems work...
Por Robert Wall 2024-11-14 10:05:21 0 145
Networking
Twin Elements CBD Male Enhancement Gummies Ingredients
 Twin Elements CBD Male Enhancement Gummies Reviews – When it comes to a man's...
Por Gopal Singh 2023-08-17 09:00:54 0 1K
Outro
Trade Finance Market Valuation Of US$ 68.62 Billion By The End Of 2032
With a CAGR of 4.5% between 2022 and 2032, it is predicted that the size of the global trade...
Por Monika Kale 2024-04-29 09:54:21 0 682
Outro
Engineered Wood Market, Share, Demand and Analysis of Key Players- Analysis Forecasts to 2032
Engineered Wood Market Overview The engineered wood market is expected to gain a market value of...
Por David Miller 2023-12-15 05:04:41 0 2K